

### Claims

1. Use of fibrinogen multimers having at least 6 fibrinogen units as an ingredient of a fibrin sealant.
2. Use according to claim 1 having 6 - 15 fibrinogen units as an ingredient of a fibrin sealant.
3. Use according to claim 1 wherein the fibrinogen multimers have 6 to 9 fibrinogen units.
4. Use according to <sup>claim 1</sup> ~~any of claims 1 to 3~~ wherein the amount of fibrinogen multimers having 6 to 9 fibrinogen units is at least 5% (w/w) of total fibrinogen.
5. A method for the production of a fibrin sealant comprising fibrinogen multimers having at least 6 fibrinogen units comprising the steps of
  - resuspending cryoprecipitate
  - adding sucrose to yield a concentration of 60 to 70% (w/w),
  - adding glycine to yield a concentration of 0.1 to 0.3 M,
  - heating to 60°C for 15 - 20 hours,
  - removing the glycine and the sucrose by dialysis,
  - adding a protease inhibitor.
6. The method of claim 5, wherein the dialysis is conducted against a buffer comprising NaCl, glycine and CaCl<sub>2</sub>.

7. The method of claim 5, wherein the protease inhibitor is tranexamic acid in a concentration of 8 - 12% (w/w) and/or arginine in a concentration of 1 - 3% (w/w).
8. A fibrin sealant comprising multimeric fibrinogen of at least 6 fibrinogen units.